Liquidia Corporation
Rating
Updated: Sep 12, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requir...
Latest News
8 days ago · defenseworld.net
California State Teachers Retirement System Acquires 5,835,156 Shares of Liquidia Corporation $LQDACalifornia State Teachers Retirement System raised its holdings in shares of Liquidia Corporation (NASDAQ: LQDA) by 8,055.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,907,594 shares of the company's stock after buying an additional 5,835,156 shares during the
11 days ago · zacks.com
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
12 days ago · zacks.com
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
20 days ago · globenewswire.com
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 CongressMORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
21 days ago · globenewswire.com
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare ConferenceMORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m.
22 days ago · zacks.com
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
22 days ago · zacks.com
Is the Options Market Predicting a Spike in Liquidia Stock?Investors need to pay close attention to LQDA stock based on the movements in the options market lately.
25 days ago · gurufocus.com
Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100On August 28, 2026, Liquidia Corp (LQDA) shares experienced a decline of 3.1%, bringing the current price to $67.63. This movement occurs within a 52-week range
25 days ago · seekingalpha.com
Liquidia: A Linear Launch Priced For Exponential GrowthLiquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.
26 days ago · zacks.com
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Add to Watchlist
Select watchlists to add or remove LQDA